Education
About Us
Working with TipRanks
Follow Us
Travere Therapeutics (TVTX)
NASDAQ:TVTX
Total Valuation
Travere Therapeutics has a market cap or net worth of $1.29B. The enterprise value is $1.48B.
Market Cap$1.29B
Enterprise Value$1.48B
Share Statistics
Travere Therapeutics has 88.77M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding88.77M
Owned by Insiders1.47%
Owned by Instutions0.47%
Financial Efficiency
Travere Therapeutics’s return on equity (ROE) is -5.44 and return on invested capital (ROIC) is -68.62%.
Return on Equity (ROE)-544.28%
Return on Assets (ROA)-54.12%
Return on Invested Capital (ROIC)-68.62%
Return on Capital Employed (ROCE)-81.51%
Revenue Per Employee$605,649.351
Profits Per Employee-$835,181.818
Employee Count385
Asset Turnover0.39
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Travere Therapeutics is -4.27. Travere Therapeutics’s PEG ratio is -0.02.
PE Ratio-4.27
PS Ratio5.89
PB Ratio23.26
Price to Fair Value23.26
Price to FCF-4.06
Price to Operating Cash Flow-5.79
PEG Ratio-0.02
Income Statement
In the last 12 months, Travere Therapeutics had revenue of $233.18M and earned -$321.55M in profits. Earnings per share was -$4.10.
Revenue$233.18M
Gross Profit$215.09M
Operating Income-$321.78M
Pretax Income-$320.51M
Net Income-$321.55M
EBITDA-265.77M
Earnings Per Share (EPS)-4.10
Cash Flow
In the last 12 months, operating cash flow was -$237.47M and capital expenditures -$9.64M, giving a free cash flow of -$246.76M billion.
Operating Cash Flow-$237.47M
Free Cash Flow-$246.76M
Free Cash Flow per Share-$2.78
Dividends & Yields
Travere Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-24.65%
Earnings Yield-23.40%
Stock Price Statistics
Beta1.87
52-Week Price Change160.84%
50-Day Moving Average19.33
200-Day Moving Average16.03
Relative Strength Index (RSI)37.08
Average Volume (3m)1.81M
Important Dates
Travere Therapeutics upcoming earnings date is May 1, 2025, After Close.
Last Earnings DateFeb 20, 2025
Next Earnings DateMay 1, 2025
Ex-Dividend Date―
Financial Position
Travere Therapeutics as a current ratio of 2.08, with Debt / Equity ratio of 6.80
Current Ratio2.08
Quick Ratio2.04
Debt to Market Cap0.29
Net Debt to EBITDA-1.29
Interest Coverage Ratio-28.67
Taxes
In the past 12 months, Travere Therapeutics has paid $120.00K in taxes.
Income Tax$120.00K
Effective Tax Rate-0.04%
Enterprise Valuation
Travere Therapeutics EV to EBITDA ratio is -6.46, with an EV/FCF ratio of -5.07.
EV to Sales7.36
EV to EBITDA-6.46
EV to Free Cash Flow-5.07
EV to Operating Cash Flow-7.23
Balance Sheet
Travere Therapeutics has $370.70M in cash and marketable securities with $401.58M in debt, giving a net cash position of $30.88M billion.
Cash & Marketable Securities$370.70M
Total Debt$401.58M
Net Cash$30.88M
Net Cash Per Share$0.35
Tangible Book Value Per Share-$0.57
Margins
Gross margin is 100.00%, with operating margin of -137.51%, and net profit margin of -137.90%.
Gross Margin100.00%
Operating Margin-137.51%
Pretax Margin-137.45%
Net Profit Margin-137.90%
EBITDA Margin-113.98%
EBIT Margin-132.66%
Analyst Forecast
The average price target for Travere Therapeutics is $34.91, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$34.91
Price Target Upside133.98%
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast17.27%
EPS Growth Forecast10.01%